2-Chloroethyl Ethyl Ether | CAS:628-34-2

We serve 2-Chloroethyl Ethyl Ether CAS:628-34-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Chloroethyl Ethyl Ether

Chemical Name:2-Chloroethyl Ethyl Ether
CAS.NO:628-34-2
Synonyms:2-Chloroethyl Ethyl Ether
1-chloro-2-ethoxyethane
Ethane, 1-chloro-2-ethoxy-
Molecular Formula:C4H9ClO
Molecular Weight:108.56700
 
Physical and Chemical Properties:
Density:0.989
Melting point:-60ºC
Boiling point:107ºC
Flash point:60°F
Index of Refraction:1.411
 
Specification:
Appearance:Colorless to pale yellow transparent liquid
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Bilatex intermediate



Contact us for information like 2-Chloroethyl Ethyl Ether chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethane, 1-chloro-2-ethoxy- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Chloroethyl Ethyl Ether Use and application,1-chloro-2-ethoxyethane technical grade,usp/ep/jp grade.


Related News: Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.Hexadecyltrimethoxysilane manufacturer When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant.p-Phenylenediamine supplier When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant.4,4'-Dibromotriphenylamine vendor Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.